Compare Gilead Sciences, Inc. (GILD) vs SPDR Kensho Final Frontiers ETF (ROKT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs SPDR Kensho Final Frontiers ETF — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.09B), while SPDR Kensho Final Frontiers ETF trades at $102.84 (market cap $176.19M). The key difference: Gilead Sciences, Inc. is far larger — about 1033.5× SPDR Kensho Final Frontiers ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while SPDR Kensho Final Frontiers ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and SPDR Kensho Final Frontiers ETF for 8 Days on average.
| GILD | ROKT | |
|---|---|---|
Market Cap | $182.09B | $176.19M |
Volume | 4,960,247 | 34,479 |
Sector | Health | Sector/Thematic |
52-Week High | $155.80 | $136.68 |
52-Week Low | $116.74 | $72.93 |
Typical Hold Time | 111 Days | 8 Days |
Enterprise Value | $205.15B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About SPDR Kensho Final Frontiers ETF
SPDR Kensho Final Frontiers ETF seeks exposure to companies supporting exploration of outer space and the deep sea. Its holdings include businesses involved in aerospace, defense, communications, research, and related technologies.
Read more on ROKT →
